COMMUNIQUÉS West-GlobeNewswire

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
28/09/2026
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating [...]
Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
28/09/2026
Expands Company’s Portfolio of Advanced Neurovascular Catheters to Support Treatment in Smaller and More Distal Anatomies WEST JORDAN, Utah, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held [...]
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
28/09/2026
Initial data expected in the first half of 2027 LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing [...]
Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Associated with Reductions in Pain Scores, Opioid Use and Overall Patient Burden
28/09/2026
POMPANO BEACH, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the publication of a milestone study, Peripheral Nerve [...]
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
28/09/2026
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
28/09/2026
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships [...]
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
28/09/2026
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection DARE-HPV Phase 2 study underway with topline results expected [...]
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
28/09/2026
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown Findings validate that physiological lipoprotein levels are sufficient [...]
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
28/09/2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
DLH Awarded New NIH Cybersecurity Operations Task Order Valued at Up to $19.1 Million
28/09/2026
ATLANTA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today [...]
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
28/09/2026
Company Reaffirms Fiscal Year 2026 Guidance CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled [...]
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
28/09/2026
Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPF LA JOLLA, CA, Sept. 28, 2026 (GLOBE [...]
Transactions under Novonesis’ share buyback program
28/09/2026
Please read the announcement in PDF Attachment 2026_19_Share_buyback
Lifecore Biomedical to be Acquired by Webster Equity Partners
28/09/2026
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at Closing [...]
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
28/09/2026
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease Three moderated posters to showcase gut-targeted exposure, favorable safety and [...]
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
28/09/2026
AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system SARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE [...]
Hyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem
28/09/2026
DALLAS, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced it has been named a launch partner for Frontier’s Hyperliquid Vault, a new membership [...]
EnerSyn Global Inc. Announces Second Nigeria Energy Investment: Lagos CNG Mother Station Project
28/09/2026
BETHESDA, MD, Sept. 28, 2026 (GLOBE NEWSWIRE) -- EnerSyn Global Inc. (Nasdaq: ESYN) ("ESYN" or the "Company," and formerly known as HWH International Inc.) announced plans today to add a second energy project. On [...]
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
28/09/2026
Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026 FDA [...]

Pages